Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia

This study evaluates the efficacy and safety of ultrasound-guided stellate ganglion block (SGB) as an adjunctive treatment for patients with treatment-resistant fibromyalgia. Patients who continue to experience significant symptoms despite stable duloxetine therapy (60 mg/day) were randomized to receive either ultrasound-guided SGB or a sham control procedure. The study aims to determine if SGB can provide clinically meaningful improvements in fibromyalgia impact and pain intensity compared to a sham injection.

NCT Number	NCT07343128
Lead Sponsor	Sanliurfa Education and Research Hospital
Conditions	Fibromyalgia
Enrollment	68 participants
Start Date	2025-06-01
Primary Completion	2025-12-25 (estimated)
Study Completion	2025-12-25 (estimated)
Updated on ClinicalTrials.gov	2026-01-16